Study drug VO659 for SCA1, SCA3, and Huntington disease
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This early-phase study tests whether VO659 is safe and how the body processes it in people with certain genetic movement disorders (SCA1, SCA3, or Huntington disease). It may help researchers learn the right dose and whether the drug can be given safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent and understand the study (age 25 to 60).
- You have genetically confirmed SCA1, SCA3, or Huntington disease (based on a specific DNA test showing long CAG repeats).
- Your disease stage must fit one of these: SCA1/SCA3 mild–moderate with SARA 3–18, or Huntington early stage with TFC 11–13 and specific confidence level.
- You must be able to do study procedures and assessments, including possible MRI scans and a likely lumbar puncture (spinal tap).
- You cannot have certain other genetic disorders caused by other specific CAG-related disease genes.
- You must not have certain safety risks (like serious migraine history, bleeding problems, significant heart rhythm/QT concerns, certain recent suicide risk, or prior antisense/siRNA treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SKY-0515 in people with Huntington's disease. The goal is to see if it can safely improve symptoms or slow the disease down.
This trial tests a gene therapy called SPK-10001 for people with early-stage Huntington's disease. It aims to slow the progression of symptoms by targeting the genetic cause of the disease.
This study follows people with certain types of spinocerebellar ataxia (a group of conditions that cause progressive movement problems) to understand how the disease changes over time and how genes might influence it. It may help researchers learn more about these conditions and support future treatments.
This study is collecting tiny particles called extracellular vesicles from blood and spinal fluid to learn more about Huntington's disease. It aims to find better ways to measure the disease in people who have HD and in those who do not.
This trial tests if a vitamin B3-like supplement, nicotinamide riboside, can help people with early to mid-stage Huntington's disease. You will be randomly assigned to take the supplement or a placebo to see if it slows the disease.
This study uses special brain imaging and memory/thinking tests to find early “markers” that can predict how Huntington’s disease will progress over time. You may qualify as someone with early-stage Huntington’s or as a healthy control, if you meet specific safety and scoring requirements.
Hear when a new Spinocerebellar Ataxia Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.